The University of Texas M.D. Anderson Cancer Center
Opportunities in Cancer Early Detection and Biomarker Translational Research
Cancer screening has potential to detect cancer at curable stage therefore holds the largest promise in cancer mortality reduction. Cancer biomarkers are measured from body
fluid (blood, urine, stool, saliva, etc.) containing signal of the existence of cancer. Examples are AFP for liver cancer, CA125 for ovarian cancer, Stool DNA panel (Cologuard) for colorectal cancer. However, rigorous evaluation of a biomarker’s clinical utility for cancer screening is challenging due to low
incidence of cancer in screening populations, and low signal from cancer at asymptomatic stage.
NCI established Early Detection Research Network (EDRN) in 2000 to accelerate the validation of cancer early detection biomarkers and move them from lab bench to clinics. I will describe how statisticians can help the field and the consortium toward
its mission. We developed biomarker development guideline and study design standards that have been used widely. Statistical methodology development has also been motivated by the scientific and clinical needs from the consortium, including biomarker group sequential equations, time dependent ROC analysis,
novel graphic display of biomarker performance, and longitudinal biomarker analysis.
In addition to continuation as the statistical coordinating center for the EDRN, we are recently funded as statistical coordinating centers for the Consortium to study Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC), and Texas Hepatocellular carcinoma consortium (THCCC). We are helping consortia to
address important clinical needs of the nation and of the state of Texas. We are also evaluating biomarker for lung cancer early detection. There are plenty opportunities for gifted statisticians, faculty, postdocs, and students to collaborate and make contributions.
Short Bio: Ziding Feng is a Professor in the Department of Biostatistics, MDACC. His research interest in his earlier career was in the statistical methods for finite mixture models and group randomized trials. In the last 15 years, his focus has been in the
evaluation of biomarkers for cancer risk assessment, early detection and diagnosis, and prognosis. He is currently leading three NIH grants in this area. He is a fellow of American Statistical Association.
Monday, October 17, 2016
4:00 PM to 5:00 PM
Duncan Hall, RM1070